Electrocore Stock News

Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020

ElectroCore (NASDAQ:ECOR) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close.The consensus EPS Estimate is -$0.07 (+50.0% Y/Y) and the…

In the last trading session, 1.03 million shares of the electroCore Inc. (NASDAQ:ECOR) were traded, and its beta was 0.93. Most recently the company’s share price was $0.51, and it changed around $0.01 or 3.23% from the last close, which brings the market valuation of the company to $37.69M. ECOR currently trades at a discount … electroCore Inc.: Why Investors Shouldn’t Get Rid Of ECOR Stock In 2022 Read More »

ROCKAWAY, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team wi

In last trading session, electroCore Inc. (NASDAQ:ECOR) saw 0.38 million shares changing hands with its beta currently measuring 0.94. Company’s recent per share price level of $0.58 trading at $0.04 or 8.07% at ring of the bell on the day assigns it a market valuation of $42.72M. That closing price of ECOR’s stock is at … electroCore Inc. (NASDAQ:ECOR) Up 3.91% Over A Week, Now Can The Stock Hit Well Above $0.0219? Read More »

Major neurostimulation devices market players include Abbott, Boston Scientific, IntraPace, Laborie, LivaNova, Medtronic, Neuronetics, SPR Therapeutics, Cyberonics, ElectroCore Inc., Aleva Neurotherapeutics SA, Synapse Biomedical Inc., MicroTransponder, RS Medical, Helbling holding Ag, EndoStim Inc., and BioControl Medical. SELBYVILLE, Del. , Jan. 20, 2022 /PRNewswire/ -- The neurostimulation devices market size is anticipated to record a valuation of USD 13.6 billion by 2027, according to the most recent study by Global Market Insights Inc. Increasing adoption and introduction of advanced neurostimulation devices will drive the overall market growth. Increasing demand for minimally invasive surgeries in developed countries attributed to the rising preference among patients for shorter hospital stays and faster recovery will accelerate the neurostimulation devices market expansion. Neurological patients using minimally invasive techniques, have experienced reduced treatment costs, less pain, and speedy recovery.

electroCore (ECOR) anticipates FY21 revenue to be ~$5.5M (consensus $5.3M), +55% Y/Y.100 VA and DoD military treatment facilities have purchased gammaCore products through December

electroCore skyrocketed today after the FDA gave its PTSD treatment a breakthrough designation. ECOR stock closed up 60% on the news!

The FDA has granted Breakthrough Designation to ElectroCore Inc''s (NASDAQ: ECOR ) gammaCore nVNS device for posttraumatic stress disorder (PTSD). The device showed a reduction of symptoms of Full story available on Benzinga.com

electroCore (ECOR) has added ~8.1% in the pre-market after announcing that the FDA granted the Breakthrough Designation for its gammaCore nVNS device as a treatment for posttraumatic

Which penny stocks are you watching right now? The post 3 Top Penny Stocks to Add to Your Watchlist in Mid-January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

ROCKAWAY, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR ), a commercial-stage bioelectronic medicine company, today announced that its gammaCore nVNS device has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for the treatment of posttraumatic stress disorder (PTSD) after showing a reduction of symptoms of PTSD by 31% when compared to sham. PTSD is a highly prevalent and disabling disorder with limited approved treatment options. According to the U.S. Department of Veterans Affairs National Center for PTSD, approximately 15 million adults in the U.S. experience PTSD each year. In the Military and Veterans Administration alone, PTSD is reported to affect between 10-20% of veterans who served in each Operations Iraqi Freedom (OIF) and Enduring Freedom (OEF), the Gulf War (Desert Storm), and the Vietnam War. More than half of all patients with PTSD report severely impaired quality of life in areas including mood, social and family relationships, leisure activities, sense of well-being and life satisfaction.

The FDA has granted Breakthrough Designation to ElectroCore Inc's (NASDAQ:ECOR) gammaCore nVNS device for posttraumatic stress disorder (PTSD). The device showed a reduction of symptoms of PTSD by

electroCore is a developer and marketer of non-invasive vagus nerve stimulation devices for the treatment of pain. The Company's gammaCore nVNS device is approved for cluster headache, and recently re